3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
3
Prostatic Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Ovarian Neoplasms
1
Ototoxicity
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Atherosclerosis
1
Interventions
sacubitril and valsartan sodium hydrate drug combination
3
Nutrition Assessment
3
Exercise
3
Carvedilol
3
dapagliflozin
2
Standard of Care
2
Rituximab
2
Ivabradine
2
Control Groups
2
Atorvastatin
2
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
acalabrutinib
1
Vincristine
1
Valsartan
1
Trastuzumab
1
Surveys and Questionnaires
1
Spironolactone
1
Sodium Chloride
1
Simendan
1
Secondary Prevention
1
Resistance Training
1
Pyruvic Acid
1
Prednisolone
1
Practice Guidelines as Topic
1
Population Groups
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Heart Failure
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03186404
2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2
Unknown
112 enrolled